Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

anti-

anti- is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 340
News articles 0
Drug details — anti-
Class
—
Route
—
Patents
20
Programs
340
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

anti- is an FDA-listed pharmaceutical active ingredient.

Key facts

INN anti-

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 060103 Phase 3 · Takeda · Hemophilia A
  2. 060401 Phase 3 · Takeda · Hemophilia A
  3. 061002 Phase 3 · Takeda · Hemophilia A
  4. 223529 Phase 3 · GSK Glaxo Smith · Asthma with type 2 inflammation characterized by an eosinoph
  5. 241502 Phase 3 · Takeda · Hemophilia A
  6. 299AR301 Phase 3 · Biogen · Kidney Transplant Recipients with Late Antibody-Mediated Rej
  7. 6630-9450-01 Phase 3 · MEDICE Arzneimittel Pütter · acute pharyngitis
  8. 6630-9450-01 Phase 3 · MEDICE Arzneimittel Pütter · acute pharyngitis

Related patents

Browse patents

  1. US 20260144885

    ANTI-LRRC15 ANTIBODIES AND USES THEREOF

    Expires Wed May 23 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2026107143

    COMBINAISON DE DOSES FIXES D'ANTICORPS ANTI-FUCOSYL-GM1 ET D'ANTICORPS ANTI-PD-1 ET SES UTILISATIONS

    Expires Wed May 16 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2026075950

    SCHÉMA POSOLOGIQUE POUR AGENT ANTI-DLL3

    Expires Wed Apr 04 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2026062034

    NANOPARTICULES DE PROTÉINE AFFICHANT DES ANTIGÈNES DE MALADIE DE LYME

    Expires Wed Mar 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2026057739

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET DES ANTICORPS ANTI-PD-1 POUR LE TRAITEMENT DU CANCER DE L'OVAIRE RÉSISTANT AU PLATINE

    Expires Wed Mar 14 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. WO 2026041780

    POLYTHÉRAPIE COMPRENANT DES ANTICORPS ANTI-CTLA4 ET UNE CHIMIOTHÉRAPIE POUR LE TRAITEMENT DU CANCER

    Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2026041793

    PROTÉINES CHIMÉRIQUES COMPRENANT DES DOMAINES PROTÉIQUES NON HUMAINS POUR AMÉLIORER L'ANTIGÉNICITÉ

    Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 20260042800

    ANTIMICROBIAL PEPTIDOMIMETICS

    Expires Wed Feb 07 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2026015882

    FRAGMENTS D'ANTIGÈNE HSV ET PROCÉDÉS ASSOCIÉS

    Expires Wed Jan 10 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. EP 4670742

    ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE

    Expires Tue Dec 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. WO 2025265012

    COMPOSITIONS COMPRENANT DES ANTICORPS ANTI-PCSK9

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2025262150

    MOLÉCULES DE RECRUTEMENT D'ANTICORPS

    Expires Thu Dec 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. WO 2025238218

    VECTEURS VIRAUX CODANT POUR DES NANOPARTICULES DE PROTÉINE D'AFFICHAGE D'ANTIGÈNE

    Expires Wed Nov 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2025238221

    VECTEURS VIRAUX CODANT POUR DES NANOPARTICULES DE PROTÉINE À PRÉSENTATION D'ANTIGÈNES MULTIPLES

    Expires Wed Nov 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. WO 2025202022

    INHIBITEURS DE L'INTERACTION ENTRE RAS ET SOS1 À BASE DE QUINAZOLINE, MACROCYCLIQUES ET ANTICANCÉREUX

    Expires Wed Sep 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12428470

    Compositions containing activatable antibodies

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12428480

    Anti-CD19 antibodies and multi-specific binding proteins

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. WO 2025198916

    ANTICORPS ANTI-TAU

    Expires Wed Sep 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12421310

    CD47 binding agents

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is anti-?

anti- is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.